June 20, 2024 03:12 PM EDT

Zealand Pharma hits early efficacy goal for amylin weight loss candidate

Nicole DeFeudis

Editor

Zealand Pharma’s amylin analogue weight loss candidate petrelintide helped patients lose a mean 8.6% of their body weight in a Phase 1b trial, meeting executives …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Zealand Pharma hits early efficacy goal for amylin weight loss candidate

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

Novo Nordisk CEO skeptical of PBM promises in Senate hearing on weight loss drug prices

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Zealand Phar­ma hits ear­ly ef­fi­ca­cy goal for amylin weight loss can­di­date

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Zealand Pharma hits early efficacy goal for amylin weight loss candidate